Top Page
Cann Group
(Sydney:CAN)
Cann Group (CAN) vs. iShares MSCI Australia ETF (EWA)
Cann Group Business Overview & Revenue Model
Cann Group Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 15.51M | 15.37M | 13.78M | 6.41M | 4.29M | 647.22K | Gross Profit |
| -3.96M | 3.19M | 20.63M | 11.24M | 4.25M | 6.22K | EBIT |
| -13.19M | -27.50M | -37.25M | -29.07M | -23.50M | -16.64M | EBITDA |
| -9.43M | -35.54M | -17.76M | -19.79M | -17.29M | -13.91M | Net Income Common Stockholders |
| -47.60M | -51.24M | -33.79M | -26.47M | -25.10M | -16.94M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 60.00K | 1.64M | 765.00K | 1.91M | 3.10M | 1.55M | Total Assets |
| 84.97M | 92.77M | 129.47M | 139.66M | 101.79M | 76.40M | Total Debt |
| 72.36M | 72.47M | 60.97M | 47.16M | 680.00K | 9.32M | Net Debt |
| 72.30M | 70.83M | 60.20M | 45.25M | -2.42M | 7.77M | Total Liabilities |
| 78.65M | 78.85M | 70.20M | 54.76M | 9.92M | 15.33M | Stockholders Equity |
| 6.32M | 13.92M | 59.26M | 84.90M | 91.87M | 61.07M |
| Cash Flow | Free Cash Flow | ||||
| -13.90M | -17.69M | -25.94M | -65.60M | -37.10M | -51.98M | Operating Cash Flow |
| -13.65M | -15.19M | -22.84M | -20.43M | -20.83M | -17.62M | Investing Cash Flow |
| 3.43M | 1.18M | -28.00K | -45.16M | -17.08M | -34.36M | Financing Cash Flow |
| 8.53M | 14.77M | 21.71M | 64.41M | 39.47M | 7.15M |
Cann Group Technical Analysis
Cann Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$45.70M | 20.29 | 4.85% | ― | 5.76% | -79.76% | |
54 Neutral | $5.37B | 3.35 | -45.10% | 2.79% | 16.77% | -0.01% | |
45 Neutral | AU$21.39M | ― | -218.38% | ― | -14.30% | 29.69% | |
39 Underperform | AU$4.26M | ― | ― | -49.04% | 32.85% | ||
38 Underperform | $8.71M | ― | -164.01% | ― | -18.80% | -46.65% |
Cann Group Corporate Events
Cann Group Limited announced the cessation of several securities due to the lapse of conditional rights, as the conditions for these securities were not met or became incapable of being satisfied. This cessation involves a total of 3,795,886 securities, impacting the company’s issued capital and potentially affecting stakeholder interests.
Cann Group Limited announced the issuance of 49,376,573 unquoted options, set to expire on June 4, 2027, with an exercise price of $0.03. This issuance is part of a previously announced transaction, indicating strategic financial maneuvers to support the company’s growth and operational objectives. The move could potentially impact the company’s market positioning by enhancing its financial flexibility and offering stakeholders an opportunity for future engagement.
Cann Group Limited has resolved its legal dispute with Rua Biosciences Limited by entering into a confidential deed of settlement and release, which includes mutual release from claims and two commercial agreements for Cann to supply medicinal cannabis products to Rua for distribution in Australia and New Zealand. This settlement not only resolves the dispute but also establishes a new commercial relationship between the two companies, potentially impacting their operations and market positioning positively.
Cann Group Limited has announced the issuance of 7,924,832 unquoted equity securities in the form of options set to expire on June 2, 2027, with an exercise price of $0.0508. This move is part of previously announced transactions and is not intended for quotation on the ASX, potentially impacting the company’s financial strategy and stakeholder interests by expanding its equity base.
Cann Group Limited has announced the issuance of 1,746,147 unquoted equity securities in the form of options set to expire on June 2, 2027, with an exercise price of $0.0573. This issuance is part of a previously announced transaction and is not intended to be quoted on the ASX, potentially impacting the company’s financial strategy and stakeholder interests by expanding its equity base.
Cann Group Limited announced the results of its General Meeting, where all resolutions were passed following a poll vote. The meeting included significant decisions such as the election of a director and the ratification of share and option issuances, which are expected to impact the company’s strategic direction and stakeholder interests positively.
Cann Group Limited announced a presentation by CEO Jenni Pilcher at their Extraordinary General Meeting, focusing on the company’s operations, sales, funding, and strategy. This announcement highlights the company’s ongoing efforts to strengthen its market position and operational capabilities, potentially impacting its stakeholders positively.
Cann Group Limited has announced the application for quotation of 11,607,322 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of May 20, 2025. This move is part of the company’s strategic efforts to bolster its financial position and enhance its market presence, potentially impacting its operations and offering new opportunities for stakeholders.
Cann Group Limited announced the quotation of 7,676,567 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective April 30, 2025. This move is expected to enhance the company’s capital structure and provide additional liquidity, potentially strengthening its market position and offering more opportunities for stakeholders.
Cann Group Limited has announced an Extraordinary General Meeting (EGM) scheduled for May 30, 2025, to seek shareholder approval for several resolutions related to recent financing transactions. These include ratifications and approvals for the issuance of shares and options as part of private placements and convertible notes, aimed at securing funding to optimize production and support strategic growth. The board supports these resolutions, which are expected to provide the company with the flexibility to pursue future expansion and growth opportunities.
Cann Group Limited announced the outcomes of a pilot clinical trial investigating medicinal cannabis as a treatment for Tourette syndrome in adolescents. Conducted by the Murdoch Children’s Research Institute and the Royal Children’s Hospital, the trial showed preliminary evidence supporting the efficacy and safety of medicinal cannabis, with high levels of acceptability reported by parents. The study suggests the feasibility of using medicinal cannabis for Tourette syndrome, recommending further research with a larger cohort to confirm these findings.
Cann Group Limited has secured an $836,469 funding advance from Radium Capital, which provides early access to its expected R&D Tax Incentive for FY2025. This advance will support the company’s strategy of supplying the medicinal cannabis market with unique products, including those sold under its Botanitech brand in collaboration with Chemist Warehouse outlets. The advance, under a loan agreement with a 15% annual interest rate, will be repaid upon receipt of the R&D Refund or by 31 October 2025. This move is expected to bolster Cann Group’s operations and strengthen its market positioning in the medicinal cannabis industry.
Cann Group Ltd. has announced the application for quotation of 41,876,573 ordinary fully paid securities on the Australian Securities Exchange (ASX) as part of a previously announced transaction. This move is expected to enhance the company’s capital structure, potentially improving its market position and providing greater value to its stakeholders.
Cann Group Ltd. has announced a proposed issue of securities, with a maximum of 1,000 ordinary fully paid shares to be issued. This move is part of the company’s strategy to strengthen its financial position and support its operations in the medical cannabis sector. The issuance is expected to have implications for the company’s market positioning and stakeholder interests as it aims to expand its influence in the industry.
Cann Group Limited has issued a prospectus for the offer of up to 1,000 new shares at an issue price of $0.017 per share, aiming to raise a maximum of $17 before costs. The document highlights that the investment is highly speculative and is not intended for distribution in the United States, emphasizing the need for potential investors to seek professional advice.
Cann Group Limited has successfully raised approximately $712,000 through a private placement, issuing shares at 1.7 cents each, a significant discount to recent trading prices. The funds will be used to expand the production of medicinal cannabis flower, supporting a new partnership with Chemist Warehouse in Queensland, and covering production costs, working capital, and offer expenses. This move is a strategic step towards strengthening Cann Group’s position as a leading supplier of medicinal cannabis in Australia.
Cann Group Limited has requested a trading halt on its securities pending an announcement related to its capital raising activities. This move is intended to help the company manage its disclosure obligations and is expected to be resolved by the commencement of normal trading on April 8, 2025, or when the announcement is made. The trading halt indicates a significant development in Cann Group’s financial strategy, potentially impacting its market positioning and stakeholders.
Cann Group Limited has signed supply agreements with eleven Chemist Warehouse pharmacy outlets in Queensland, marking a significant expansion of its market presence. These agreements, which have an initial two-year term, are expected to enhance Cann’s credibility and visibility in the marketplace, leveraging the Chemist Warehouse brand’s extensive reach and potentially leading to further expansion.
Cann Group Limited has entered into supply agreements with eleven Chemist Warehouse pharmacy outlets in Queensland. This collaboration will see Cann supplying its Botanitech range of medicinal cannabis products, enhancing its market presence and potentially boosting its growth in the medicinal cannabis sector.
Cann Group Ltd. has announced the issuance of 1,185 fully paid ordinary securities to be quoted on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to expand its market presence and enhance shareholder value by converting options and other convertible securities.
Cann Group Ltd. has announced the issuance of 7,930,438 ordinary fully paid securities, which will be quoted on the ASX. This move is part of the company’s strategy to enhance its capital structure, potentially impacting its market position and providing opportunities for stakeholders as the company continues to expand its operations in the medicinal cannabis sector.
Cann Group Ltd. has announced the appointment of Peter Kopanidis as a director, effective March 31, 2025. The announcement indicates that Mr. Kopanidis currently holds no securities or interests in the company, suggesting a fresh perspective in the board’s composition. This appointment may impact the company’s strategic direction and governance, potentially influencing its market positioning and stakeholder relations.
Cann Group Limited has announced changes to its board of directors, with Mr. Peter Kopanidis joining as a Non-executive Director and Mr. Robert Barnes retiring from the same position. Peter Kopanidis brings over 30 years of experience in finance across various industries, which is expected to be beneficial for Cann Group as it navigates its current stage of development. The board chair, Doug Rathbone, expressed gratitude for Robert Barnes’ contributions, particularly his insights into the pharmaceutical sector, and welcomed Peter’s expertise in corporate finance and investor relations.
Cann Group Limited has lodged a cleansing prospectus with ASIC and ASX for the issuance of convertible notes, options, and placement shares, following a recent drawdown of convertible securities. The primary aim is to remove on-sale restrictions related to the proposed securities issuance, potentially impacting the company’s financial flexibility and market operations.
Cann Group Ltd. has announced a prospectus for an offer involving convertible notes, ordinary shares, and options, aiming to raise a total of $600,000. This strategic financial move is intended to bolster the company’s capital, potentially impacting its market position and offering stakeholders an opportunity for speculative investment.
Cann Group Ltd. announced a proposed issue of securities, including convertible notes and unquoted options, as well as ordinary fully paid shares. This move is likely aimed at raising capital to support its operations and growth initiatives, potentially strengthening its market position in the medicinal cannabis sector.